heor.tv inteviewed Marilyn Dix Smith, Founding Executive Director of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and asked about its impact on patient healthcare.
Details‘Ghostwriting’ is a contentious issue among both medical practitioners and medical writers. Outside these circles, this issue typically only surfaces when either a politician decides to deplore it or a pharmaceutical company is implicated.
DetailsThe statistics are staggering. According to one study, the average office worker is interrupted every 11 minutes and takes 25 minutes to return to the original task. Another estimate is…
DetailsDuncan Dibble and Ruth Whittington speak to Jeff Trotter about observational research and its place in the changing health technology assessment (HTA) environment. heor.tv is a collaboration between http://www.healtheconomicsdigest.com and https://www.rxcomms.com
Detailsheor.tv interview Diana Brixner, former president of ISPOR and asked her how important good communications are with respect to rational decision making in the context of evidence supporting market access and reimbursement.
DetailsDuncan Dibble interviewed Judith Hargreaves, Associate Director for Global Health Economics and Outcomes Research at Ethicon Products about her approach to the customer base in light of the Health Technology Assessment (HTA) landscape.
Detailsheor.tv polled Mark Sculpher and Ameet Bakhai with regards to what value based pricing means to them by providing some perspective on the subject.
DetailsAs part of the heor.tv inteview with Jim Furniss, they asked about his thoughts on Value Based Pricing in the UK and what considerations should be mindful of before implementation in 2014.
Detailsheor.tv interviewed Jim Furniss, Director of Market Access at Bridgehead International and asked what effect the global recession has had on pricing, reimbursement and market access.
Detailsheor.tv ask Marjolein Pompen what the current pricing and reimbursement activities she is doing now as opposed to previously in order to keep drugs in the Dutch market.
Details
